From: Results of a phase II open-label, non-randomized trial of cisplatin chemotherapy in patients with BRCA1-positive metastatic breast cancer
Toxicity
N (%)
Neutropenia
Grade 1
1
Grade 2
4
Grade 3
Grade 4
Any
7 (35%)
Nausea/vomiting
6
10 (50%)
Anemia
0
1 (5%)
Neurotoxicity
2
6 (30%)